Form 4: Cingulate Inc. Executive Receives Stock Options
SEC Form 4
Raul R. Silva, EVP and CSO of Cingulate Inc., was granted 1,000 stock options on December 31, 2024.
Summary
- Raul R. Silva, the Executive Vice President and Chief Scientific Officer of Cingulate Inc., received 1,000 stock options.
- The stock options were granted on December 31, 2024, with an exercise price of $4.93 per share.
- The options vest immediately and expire on December 31, 2034.
- The grant was made under the terms of Dr. Silva's employment agreement.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no indications of negative news or concerns.
Positives
- The granting of stock options to a key executive like the CSO can be seen as a positive incentive to align their interests with the company's success.
- The long expiration date of the options, December 31, 2034, suggests a long-term commitment from the executive.
Risks
- The exercise of these options could potentially dilute existing shareholders if the company's share price increases significantly.
Management Comments
- The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with the company's long-term performance.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in the biotech industry, often used to attract and retain talent.
- The vesting and expiration terms are typical for such grants, with a 10-year expiration period being common.
Stakeholder Impact
- Shareholders may view this as a positive sign of incentivizing management.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date the stock options were granted and the date they become exercisable. |
| 12/31/2034 | Expiration date of the stock options. |
| 01/07/2025 | Date the Form 4 was signed. |
Keywords
stock options, executive compensation, insider trading, Cingulate Inc., Raul R. Silva, EVP, CSO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.